Results 81 to 90 of about 74,157 (302)

Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis [PDF]

Hospital Pharmacy, 2017
Rheumatoid arthritis (RA) is a disease where the immune system attacks the linings of the joints, resulting in joint pain, stiffness, swelling, and destruction. Although many products are available for the treatment of RA, limitations such as adverse reactions and tolerance greatly affect adherence.
Senir, Turan, Scot, Walker
openaire   +2 more sources

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition [PDF]

, 2012
Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor–like ...
Baffert, Fabienne, Bird, Liat, Bradner, James Elliott, Chapuy, Bjoern, Christie, Amanda L., De Pover, Alain, Ebel, Nicolas, Eck, Michael Joseph, Erdmann, Dirk, Evrot, Emeline, Gaul, Christoph, Hofmann, Francesco, Kopp, Nadja, Kung, Andrew, Lane, Andrew Alan, Levine, Ross L., Marubayashi, Sachie, McKeown, Michael Robert, Murakami, Masato, Paranal, Ronald M., Radimerski, Thomas, Romanet, Vincent, Régnier, Catherine H., Sallan, Stephen Earl, Tiedt, Ralph, Toms, Angela Vivian, van Bodegom, Diederik, Vangrevelinghe, Eric, Weigert, Oliver, Weinstock, David Marc, Yoda, Akinori   +30 more
core   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source

TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]

, 2019
BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang, Godec, Abigail, Hirbe, Angela C, Qin, Wenjing, Shao, Jieya, Tao, Yu, Zhang, Xiaochun, Zhu, Cuige   +7 more
core   +2 more sources

Differences in SARS‐CoV‐2 antigen persistence in individuals with systemic autoimmune rheumatic diseases compared to the general population: A RECOVER‐Adult Cohort Study

Arthritis &Rheumatology, Accepted Article.
Background Individuals with systemic autoimmune rheumatic diseases (SARDs) are at risk for worse acute and post‐acute COVID‐19 outcomes, though whether individuals with SARDs have longer persistence of viral antigens after COVID‐19 has not been studied.
Naomi J. Patel, Zoe Swank, Jiaqi Wang, Xiaosong Wang, Lauren A. O'Keeffe, Madison Negron, Liya S. Getachew, Louise L. Hansen, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie A. Davis, Kathleen M.M. Vanni, Sandria Savage, Julie S. Lam, Zachary S. Wallace, David R. Walt, Jeffrey A. Sparks, RECOVER‐Adult   +18 more
wiley   +1 more source

Modern Management Approaches for Alopecia Areata

Вопросы современной педиатрии
Alopecia areata is a chronic genetically determined inflammatory autoimmune disease damaging hair follicles and leading to temporary or persistent nonscarring hair loss.
Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasiya D. Alekseeva, Olga B. Gordeeva, Leyla S. Namazova-Baranova   +4 more
doaj   +1 more source

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor [PDF]

, 2019
The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly ...
Battelli, Nicola, Cheng, Liang, Cimadamore, Alessia, Di Nunno, Vincenzo, Gatto, Lidia, López-Beltrán, Antonio, Massari, Francesco, Mollica, Veronica, Montironi, Rodolfo, Santoni, Matteo, Scarpelli, Marina   +10 more
core   +3 more sources

T cells, the next big target in axSpA?

Arthritis &Rheumatology, Accepted Article.
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells.
Mansi K. Aparnathi, Nigil Haroon
wiley   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

A novel treatment for psoriatic arthritis: Janus kinase inhibitors

Chinese Medical Journal, 2020
. Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis which is associated with psoriasis. The early recognition and treatment for PsA are of critical importance.
Miao Chen, Sheng-Ming Dai, Li-Shao Guo
doaj   +1 more source